BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ng IK, Kumarakulasinghe NB, Syn NL, Soo RA. Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. J Clin Pathol 2021;74:116-22. [PMID: 32576630 DOI: 10.1136/jclinpath-2020-206754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Du X, Bai H, Wang Z, Daun J, Liu Z, Xu J, Chang G, Zhu Y, Wang J. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs. Thorac Cancer 2022. [PMID: 35347870 DOI: 10.1111/1759-7714.14380] [Reference Citation Analysis]
2 Liao ZX, Kempson IM, Hsieh CC, Tseng SJ, Yang PC. Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer. Drug Discov Today 2021:S1359-6446(21)00322-6. [PMID: 34325010 DOI: 10.1016/j.drudis.2021.07.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
3 Nasako H, Takashina Y, Eguchi H, Ito A, Ishikawa Y, Matsunaga T, Endo S, Ikari A. Increase in Toxicity of Anticancer Drugs by PMTPV, a Claudin-1-Binding Peptide, Mediated via Down-Regulation of Claudin-1 in Human Lung Adenocarcinoma A549 Cells. Int J Mol Sci 2020;21:E5909. [PMID: 32824620 DOI: 10.3390/ijms21165909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]